Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Brain and Central Nervous System Tumors: early-phase trial registry
1 of 55 indexed Brain and Central Nervous System Tumors trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #254 of 28,707 conditions by registered trial count.
55 US clinical trials · 1 currently recruiting · #254 of 28,707 conditions by registered trial count
Brain and Central Nervous System Tumors: 55 US clinical trials tracked, 1 recruiting.
Brain and Central Nervous System Tumors is the subject of 55 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 40 in Phase 1-2 (earlier-stage). The most active sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, running 6 of these trials.
Enrollment posture brief
Registry condition brain-and-central-nervous-system-tumors
OPEN 1 | RECR 2% | LATE 7 | EARLY 40 | RANK #254 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Coronary Disease (3% recruiting · 36 trials)
Brain and Central Nervous System Tumors lists 1 open slots (2% of 55 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Brain and Central Nervous System Tumors on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Brain and Central Nervous System Tumors is recruiting below its size-band peers.
1 of 55 indexed trials (1.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Brain and Central Nervous System Tumors trials is spread across many organizations.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins accounts for 6 of 55 trials (10.9%). 24 distinct sponsors appear on at least one study for this condition label.
-
Most Brain and Central Nervous System Tumors trials plan to enrol fewer than 100 people.
Median target enrolment is 53 among the 46 trials that report a genuine target (sentinel values excluded). 33 of those (71.7%) plan for fewer than 100 participants.
-
Brain and Central Nervous System Tumors research is mostly interventional.
49 interventional and 6 observational studies make up this index (89.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
55 total, page 1 of 2
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Barbara Ann Karmanos Cancer Institute
NCT00935090
Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)
European Organisation for Research and Treatment of Cancer - EORTC
NCT00626990
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Eastern Cooperative Oncology Group
NCT00978458
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
Alliance for Clinical Trials in Oncology
NCT00887146
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
St. Jude Children's Research Hospital
NCT00602667
Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors
National Cancer Institute (NCI)
NCT00031928
Study of Tissue and Blood Samples From Patients With High-Grade Glioma
Alliance for Clinical Trials in Oncology
NCT01004887
Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor
St. Jude Children's Research Hospital
NCT00085202
Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas
University of California, San Francisco
NCT00274755
Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma
Radiation Therapy Oncology Group
NCT00895622
Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas
Radiation Therapy Oncology Group
NCT00004259
Risk Factors for Developing a Blood Clot in Patients Who Are Undergoing Cancer Treatment for Newly Diagnosed Gliomas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00253669
Developing Interview Questions to Estimate Workplace Exposure to Electric and Magnetic Fields
National Institutes of Health Clinical Center (CC)
NCT00340054
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00025675
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
Vanderbilt-Ingram Cancer Center
NCT00666211
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor
St. Jude Children's Research Hospital
NCT00003211
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Alliance for Clinical Trials in Oncology
NCT00003996
Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00486603
Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders
Case Comprehensive Cancer Center
NCT00255671
Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse
Pfizer
NCT00003775
Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors
Memorial Sloan Kettering Cancer Center
NCT00470366
Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain
Duke University
NCT00003348
Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies
Alliance for Clinical Trials in Oncology
NCT00897663
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
Pediatric Brain Tumor Consortium
NCT00015899
Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme
Duke University
NCT00003464
Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor
Pediatric Brain Tumor Consortium
NCT00047177
Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00003751
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
Radiation Therapy Oncology Group
NCT00003417
O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors
National Cancer Institute (NCI)
NCT00003765
Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00404248
Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors
University of California, Davis
NCT00389584
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma
Alliance for Clinical Trials in Oncology
NCT00003621
Busulfan in Treating Children and Adolescents With Refractory CNS Cancer
Pediatric Brain Tumor Consortium
NCT00006246
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
Pediatric Brain Tumor Consortium
NCT01158300
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
City of Hope Medical Center
NCT00544284
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT00024258
Combination Chemotherapy for Patients With Brain Cancer
Dartmouth-Hitchcock Medical Center
NCT00002814
Intrathecal Busulfan in Treating Patients With Recurrent, Refractory, or Metastatic Leptomeningeal Tumors
Duke University
NCT00003462
Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor
Duke University
NCT00006342
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
Jonsson Comprehensive Cancer Center
NCT00509431
AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme
Novartis Pharmaceuticals
NCT00107237
Sirolimus in Treating Patients With Glioblastoma Multiforme
Jonsson Comprehensive Cancer Center
NCT00047073
Vaccine Therapy in Treating Patients With Malignant Glioma
Jonsson Comprehensive Cancer Center
NCT00612001
Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma
Jonsson Comprehensive Cancer Center
NCT00107185
Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma
Memorial Sloan Kettering Cancer Center
NCT00058370
Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas
Duke University
NCT00002753
Cytochlor, Tetrahydrouridine, and External-Beam Radiation Therapy in Treating Patients With Cancer That Has Spread to the Brain
Brian Lally
NCT00521183
Immunotoxin Therapy in Treating Patients With Malignant Glioma
New Approaches to Brain Tumor Therapy Consortium
NCT00006268
Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors
Texas Children's Cancer Center
NCT00003241
SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme
Pfizer
NCT00003293
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 25 |
| Phase 2 | 15 |
| Phase 3 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Brain and Central Nervous System Tumors records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Brain and Central Nervous System Tumors trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Brain and Central Nervous System Tumors page
55 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Brain and Central Nervous System Tumors trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sponsors the most Brain and Central Nervous System Tumors trials on record, review their full trial history before evaluating a specific study. See Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Brain and Central Nervous System Tumors condition card totals 55 registered trials; most-linked intervention radiation therapy; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.